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Abstract
Early detection of tumor-specific autoantibodies (auto-Abs) has the potential to be used for cancer screening and
diagnosis. Whether auto-Ab may be useful to track metastatic progression or response to treatment is, however,
largely unknown. To address these issues, the serological proteome was analyzed in an invasive but treatment-
responsive mouse tumor model. Among 40 serum-reactive proteins identified by multiplex analysis, we chose to
focus on glucose-regulated protein 78 (GRP78), a chaperone protein involved in the endoplasmic reticulum stress
response. We first validated GRP78 as a protein overexpressed and mislocalized in tumor cells. We then docu-
mented that an increase in GRP78 auto-Ab titer preceded the detection of a palpable tumor mass, correlated with
metastatic progression, and was influenced by the onset of tumor neovascularization. We also found that chemo-
therapy and radiotherapy, both leading to inhibition of tumor growth, oppositely influenced the anti-GRP78 im-
mune response. Whereas radiation increased the concentration of GRP78 auto-Ab by three-fold, the auto-Ab
titer was reduced in response to bolus or metronomic administration of cyclophosphamide. Finally, we established
a decrease in auto-Ab–producing B lymphocytes in response to chemotherapy and the overexpression of GRP78
together with a strong immunoglobulin response in irradiated tumors. In conclusion, we identified GRP78 auto-Ab
as an early marker of tumor andmetastatic progressions. However, the multiple influences of anticancer treatments
on the humoral immune system calls for caution when exploiting such auto-Ab as markers of the tumor response.
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Introduction
Autoantibodies (auto-Ab) are present in the blood of patients who
are affected by different malignancies [1,2]. These antibodies are
directed against a group of autologous cellular antigens generally
known as tumor-associated antigens (TAAs) [3–5]. The expression
by tumor cells of proteins, which are mutated, mislocalized, or pro-
duced in abnormal quantities, is thought to mainly account for this
humoral response. Auto-Abs circulate for a longer time than other
polypeptides because they are very stable in the serum and often pro-
duced in large amounts. Their biochemical properties are well under-
stood, and many available reagents do exist for their detection. Serum
profiling of circulating auto-Ab is therefore considered a very attrac-
tive method to diagnose cancer at early stages.
Different proteomic techniques allow detecting auto-Ab and iden-
tifying TAAs: serological expression cloning and serological proteome
analysis (SERPA) are among them [6–9]. These methods use a patient’s
sera to probe blotted phage expression libraries derived from tumor cells
or tumor cell lysates blotted onto a membrane after two-dimensional
gel separation, respectively. Modification of the latter involves spotting
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of fractionated tumor lysates onto microarrays [10], and for each of
these techniques, final identification of the proteins of interest requires
mass spectrometry. SERPA has the advantages to allow proteins with
their posttranslational modifications to be analyzed for their immuno-
genicity and to reveal, in a single experiment, the global reactivity of a
given serum toward a tumor-derived proteome. Multiple studies have
already used these techniques to identify auto-Abs in a variety of can-
cers including hepatocellular carcinoma [3], colon cancer [11,12], lung
cancer [13], and breast cancer [5,14].
Very little is known, however, about how the auto-Ab–based mark-
ers of early cancer stages do evolve when the disease progresses to
metastases or when patients undergo anticancer treatments. In the-
ory, the ideal auto-Ab candidate would have to be upregulated when
the tumor is growing or when metastases are developing and to fall
down when the patients respond to the treatment. Collateral effects
of treatments on the capacity of tumor or immune cells to contribute
to the auto-Ab response, however, should not be underestimated.
Chemotherapy may, for instance, lead to lymphodepletion and thereby
interfere with the capacity of the humoral immune system to produce
auto-Ab. Whether a reduction in auto-Ab reflects the effects of che-
motherapy on tumor growth or instead acknowledges a systemic in-
terference with the immune system needs to be addressed to fully
exploit information derived from serological proteome analyses.
Here, we applied the SERPA technique to identify the fate of
auto-Ab in tumor-bearing mice exposed to different treatments, in-
cluding chemotherapy, radiotherapy, and surgery. Such an animal
model allows to reduce interindividual serological variations under
basal conditions as well as in response to treatments and to concen-
trate in 2 to 3 weeks, the life of a tumor from the primary tumor emer-
gence to the metastases development. Using SERPA technology,
we identified glucose-regulated protein 78 (GRP78) as a reproducible
immunogenic TAA in our mouse tumor model. A specific enzyme-
linked immunosorbent assay (ELISA) was developed and confirmed
that the increase in GRP78 auto-Ab titer was correlated with primary
tumor and metastases development. Opposite variations in the GRP78
auto-Ab concentrations after chemotherapy and radiotherapy, how-
ever, pointed out how treatment-driven modulation of the immune
system may interfere with the auto-Ab production and detection.
Materials and Methods
Cells and Mice
Lewis lung carcinoma (LLc) cells were routinely cultured in
175-mm flasks in serum containing Dulbecco modified Eagle me-
dium (Invitrogen, Paisley, UK). Adult C57Bl/6J mice (Elevage Janvier,
Le Genest Saint-Isle, France) received intramuscular injections of 106
syngeneic LLc cells in the posterior right leg. The tumor diameters were
regularly tracked with an electronic caliper. Blood was collected for se-
rological assays through retro-orbital or intracardiac routes according
to the required amounts. Ten days after tumor cell injection, mice were
exposed to radiotherapy or chemotherapy. Local irradiation was ad-
ministered to mice using a RT-250 device (Philips Medical Systems,
Brussels, Belgium) with a dose delivery of 1.2 Gy/min. The tumor was
centered in a circular irradiation field, and healthy tissues were protected
by a lead mask. Two different protocols were used for chemotherapy:
cyclophosphamide (Bayer, Leverkusen, Germany) was either adminis-
tered through intraperitoneal injection of a bolus dose (100 mg/kg)
or added to the drinking water (renewed every 3 days) for a so-called
metronomic administration [15] to reach a 20-mg/kg per day regimen.
Each procedure was approved by local authorities according to national
animal care regulations.
SERPA Technique
Tumors from three different mice were pooled, lysed in difference
in-gel electrophoresis labeling buffer (7 M urea, 2 M thiourea, 4% 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, and
30 mM Tris pH 8.5), homogenized using Ultra-Turrax T25 (IKA,
Staufen, Germany), and clarified by centrifuging at 12,000g for 15min-
utes at 4°C. Protein concentration was determined by the Bradford
method, and extracts were diluted to reach a final concentration of
5 to 10 μg/μl. pH was adjusted to 8.5, and 25 μg of each sample was
labeled with 200 pmol of amine-reactive cyanine Cy5 dye (Amersham
GE Healthcare, Diegem, Belgium) for 30 minutes in the dark at 4°C,
according to the manufacturer’s instructions. Labeling reaction was
stopped by incubating the mixture for 10 minutes with 10 mM lysine
(Sigma Aldrich, Bornem, Belgium), and nonlabeled proteins were added
to reach 300 μg. Samples were then diluted in immobilized pH gra-
dient (IPG) buffer (4% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate, 7 M urea, 2 M thiourea, 30 mM Tris, 30 mM DTT,
1% IPG buffer 3-11 (vol./vol.) [Amersham GE Healthcare]) and in-
cubated for 20 minutes in the dark at room temperature.
Proteins were loaded onto rehydrated 18-cm IPGstrips pH 3-11 NL
for the isoelecteric focusing on the IPGphor; parameters were as fol-
lows: 300 V for 3 hours, gradient steps of 1000 V for 8 hours, 8000 V
for 3 hours, and 8000 V for 45 minutes at 20°C with a maximum cur-
rent setting of 50 μA per strip. IPGstrips were subsequently incubated
for 15 minutes with equilibration solutions (6 M urea, 30% glycerol,
2% SDS, 1.5 M Tris pH 8.8) supplemented with 10 mg/ml DTT
and 25 mg/ml iodoacetamide, respectively. One-dimensional strips were
then washed and loaded onto the two-dimensional gels (10% acryl-
amide). Electrophoresis was performed overnight at 15°C.
Separated proteins were finally transferred onto low-fluorescence
polyvinylidene difluoride (PVDF) membrane (200 mA for 2 hours).
All the materials and products were purchased from GE Health-
care, except glycerol which was purchased from Sigma. Blotted two-
dimensional membranes were incubated for 3 hours in 5% nonfat dry
milk containing Tris–Tween buffered saline (TTBS) blocking buffer
and were then exposed overnight to either control mouse serum or
tumor-bearing mice (dilution, 1:100); a pool of sera collected from
15 different mice was used per condition. After several washes in TTBS
containing 1% nonfat dry milk, membranes were incubated with
horseradish peroxidase–conjugated goat antimouse immunoglobulin
class G (IgG) antibody (1:5000; Jackson Immunoresearch, Sulfolk,
UK) for 2 hours. Note that this secondary antibody (cat. no. 115-
035) reacts with both heavy and light chains of IgG molecules and
may thus also react with other immunoglobulin classes, including
IgM. Immunodetection was performed using ECL Plus (GE Health-
care) followed by scanning at the Cy2 wavelength on the Ettan Dige
Imager (GE Healthcare; Figure W1).
Immunoblot Analysis and Immunocytochemistry
Collected tumors were homogenized with an Ultra-Turrax in
RIPA lysis buffer containing 1% protease inhibitor cocktail. SDS-
PAGE was performed as previously described on 10% acrylamide
gels, and after transfer, PVDF membranes were probed overnight
at 4°C with anti-GRP78 antibodies (BD Pharmingen [Erembodegem,
Belgium] and Cell Signaling [Danvers, MA]). HRP-conjugated sec-
ondary antibody was used for detection with ECL Plus.
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For immunohistochemical analyses, frozen tumor sections were
probed overnight at 4°C with anti-GRP78 antibody (dilution 1:50; Cell
Signaling) or with anti-CD31 antibody (dilution, 1:50; Pharmingen)
after a 30-minute blocking procedure in PBS containing 0.1% Tween
and 5% BSA. Detection was performed with Alexa Fluor second-
ary antibodies (dilution, 1:300); quantification was performed using
ImageJ software (National Institutes of Health, Bethesda, MD). In
some experiments, nonpermeabilized tumor sections were costained
with rhodamine-labeled wheat germ agglutinin (Vector Laboratories,
Burlingame, CA) to probe plasma membranes.
Laser Doppler Imaging
Local tumor blood flow was measured with a laser Doppler imager
(Moor Instruments, Devon, UK). Mice were anesthetized, and fur was
removed using a depilatory cream. The animals were placed on a heat-
ing pad (37°C) to minimize variations in temperature. The perfusion
of the tumor-bearing and control legs can be evaluated on the basis of
colored histogram pixels.
In-gel Enzymatic Digestion and Mass Spectrometry
Preparative gels were performed with 300 μg of unlabeled proteins
according to the protocol described above for the analytical gels.
Two-dimensional gels were krypton-stained (Pierce, Rockford, IL)
after protein fixation. The proteins of interest were automatically
picked from the gels with the Ettan Spot Picker (GE Healthcare).
After rinsing, gel pieces were dehydrated in acetonitrile and further
dried at 37°C for 20 minutes. Digestion was performed overnight
with trypsin (12.5 ng/μl) in 50 mM ammonium bicarbonate. The
extraction step was performed with formic acid 5% for 15 minutes at
37°C. Peptides were extracted with 5% formic acid at 37°C for 15 min-
utes, and the collected supernatants were kept frozen at −20°C until
mass spectrometry analysis.
Digested peptides were then processed for identification on the basis of
their mass fingerprint obtained using a matrix-assisted laser desorption/
ionization–time of flight mass spectrometry (MALDI-TOF; Waters,
Milford, MA) or using a nanoflow liquid chromatography coupled
to tandem mass spectrometry with electrospray ionization (Waters)
on a CapLC Q-TOF2 mass spectrometer (Waters; Supplementary
Data for detailed information). Full-length proteins were identified
with Mascot software (version 2.2; Matrix Sciences, London, UK) by
sequence homology research against mouse protein databases.
GRP78 ELISA
Amounts of circulating auto-Abs to GRP78 were determined by
conventional ELISA. Ninety-six–well plates (Reacti-Bind; Thermo
Scientific, Rockford, IL) were coated overnight at room temperature
with 5 μg/ml recombinant GRP78 protein (Stressgen, Ann Arbor,
MI). Coating and blocking procedures were carried out using Ultra-
block andNeptune buffers from AbD Serotec (Oxford, UK) according
to the manufacturer’s instructions. Sera (dilution, 1:100) were incu-
bated overnight at 4°C, and after washing, specific hybridization
was measured with a peroxidase-conjugated antimouse IgG antibody
(dilution, 1:10,000) and addition of 3,3′,5,5′-tetramethylbenzidine
(Merck Chemicals, Nottingham, UK). Plates were read at 450 nm
in a microplate reader (VictorX4; Perkin Elmer, Waltham, MA), and
the calibration curve was performed for each single experiment using
serial dilutions of GRP78 antibody (BD Pharmingen; Figure W2).
Immunoprecipitation and Immunodetection of Natural IgG
The same volumes of serum and protein G sepharose (slurry 1:1)
were mixed together and incubated for 1 hour at 4°C under constant
agitation. Pellets were collected by centrifuging at 10,000g at 4°C and
were resuspended in 2× Laemmli buffer. Samples were boiled for
5 minutes and were centrifuged; supernatants were analyzed by im-
munoblot analysis as described above. In some experiments, accumu-
lation of natural IgG was evaluated in tumor sections using an Alexa
Fluor 488 antimouse IgG.
Flow Cytometry Analysis
Blood samples were freshly collected, and red blood cells were elim-
inated by centrifugation onHistopaque 1083 (Sigma). Cells were then
labeled with a biotin-conjugated monoclonal antibody from BD
Pharmingen (anti-B220, clone RA3-6B2) then with PE-conjugated
streptavidin. Fluorescence signals were measured using a FACScan
apparatus (BD Pharmingen) and analyzed by the FlowJo software
(Tree Star, Inc, Olten, Switzerland).
Statistical Analysis
Data are expressed as means ± SEM or as scatter plots. Student’s
t test and one-way analysis of variance were used where appropriate.
Results
SERPA Identification of GRP78 Auto-Abs in
Tumor-Bearing Mice
Total proteins extracted from LLc tumors were separated by two-
dimensional PAGE and were transferred onto PVDF membranes.
Pooled sera from tumor-bearing mice and control mice (n = 15
per condition) were probed separately for the presence of auto-Abs
directed against tumor proteins. Multiplexing analysis was performed
taking advantage of the Cy5 prelabeling of tumor proteins and the
detection of the anti-IgG peroxidase-conjugated secondary antibody
in the Cy2 wavelength (Figure W1). The long-lasting and stable
chemiluminescence from the ECL Plus reagent used in our experi-
ments gave a stable fluorescence signal. The low interindividual
variability in this mouse tumor model led to the identification of
40 serum-labeled spots on the two-dimensional blots. The proteins
of interest were excised from preparative gels and digested with tryp-
sin, and the peptide mixtures were analyzed by mass spectrometry.
This led to the identification of 24 proteins with satisfying scores
(Table W1), among which 12 were tumor-bearing mouse serum–
positive (Table 1). Only four antigens, however, were exclusively rec-
ognized by the serum of tumor-bearing mice: GRP78, aldolase A1,
vinculin, and heterogeneous nuclear ribonucleoprotein L. In the rest
of the study, we chose to focus on GRP78 (also called BiP), which
was the antigen giving the strongest immunoblot signal (see enlarged
spot in Figure 1).
GRP78 Autoantigen Validation
The GRP78 identification was confirmed by probing two-
dimensional membranes with commercially available anti-GRP78
antibody (Figure 2A). We then examined by Western blot analysis
the GRP78 expression level in LLc tumor cells and found that it
amounted to more than five-fold the abundance in the host tissue
(Figure 2B). Furthermore, while in the host tissue, GRP78 was ex-
clusively found intracellularly in agreement with its endoplasmic re-
ticulum (ER) function; immunohistochemistry revealed that, in
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tumor cells, GRP78 was aberrantly located at the plasma membrane
(Figure 2C ).
GRP78 Auto-Abs as a Marker of Tumor Growth
An ELISA was developed using recombinant GRP78 protein to
confirm the presence of auto-Abs in the serum of tumor-bearing
mice and to track titer changes in response to treatments. Calibration
was carried out for each ELISA assay, and a linear relationship was
consistently observed in the range of antibody concentration detected
from the mouse serum (Figure W2). Blood was collected from tumor-
bearing mice on days 0, 3, 7, 10, 14, and 17 after injection (intra-
muscular) with 106 tumor cells. ELISA revealed that a net increase in
GRP78 auto-Abs was detectable in the tumor-bearing mouse serum
as soon as 3 days after tumor cell injection. Interestingly, at that early
time, tumor growth, as measured with an electronic caliper, was not
yet detectable; tumors were actually palpable from day 7 (Figure 3B).
GRP78 auto-Ab signal remained stable from day 3 to day 7 after in-
jection but peaked on day 10; values detected on days 14 and 17
were barely higher than those observed on day 7. Because day 10 is
usually the time required for angiogenesis to become functional, we
examined the difference in endothelial staining using anti-CD31 anti-
body and blood flow around this period. We confirmed a significant
increase in large, mature blood vessels on day 14 versus a punctate, an-
giogenic pattern on day 7 (Figure 3E ). A dramatic increase in tumor
blood flow was also observed between day 7 and day 14, as determined
using laser Doppler imaging (Figure 3F ).
In other series of animals aimed to examine the effect of metastases
spreading on the anti-GRP78 titer, we stimulated the development of
dormant lung metastases by surgically removing the primary tumor
(when reaching 8 mm in diameter), as previously documented in this
tumor model [16]. Interestingly, whereas a net increase in anti-
GRP78 antibody was observed 9 days after surgery (Figure 3C ),
the detection of metastases required 5 to 10 more days (see day 14
[6/9 mice] and day 19 in Figure 3D). Between day 14 and day 19,
Figure 1. SERPA of LLc tumor-bearing mice. Representative immunoblot analysis with pooled sera from tumor-bearing mice (left panel)
or control mice (right panel) (n = 15) on Cy5-labeled LLc tumor extracts; yellow/red spots correspond to proteins recognized by auto-Ab
present in the sera. This experiment was repeated four times; the enlarged spot corresponds to GRP78, as confirmed after picking,
trypsin digestion, and consecutive MALDI identification.
Table 1. List of Identified Tumor Proteins Detected by Two-dimensional Immunoblot Analysis with the Sera of Tumor-Bearing Mice
Proteins pI MW (kDa) Mascot Score Uniprot no. Queries Matched Sequence Coverage (%) P (Expect)
MALDI identification
inner membrane protein mitochondrial cra 6.18 83 148 Q8CAQ8 34 52 1.81e−12
Villin 2 5.83 69 245 P26040 41 60 4.50e−20
Grp78 4.79 72 240 P20029 36 56 1.40e−19
Heat shock protein 1 4.93 84 125 P07901 29 51 1.80e−08
Heterogeneous nuclear ribonucleoprotein l 6.07 70 161 Q499X2 22 47 5.70e−13
Heterogeneous nuclear ribonucleoprotein k 5.39 51 119 P61979 18 41 1.80e−07
Vimentin 4.77 52 225 P20152 31 59 4.50e−18
Lap 3 7.61 56 153 Q9CPY7 27 56 1.10e−10
Lectin, galactose binding, soluble 3 8.50 30 122 P16110 9 80 9.10e−08
QTOF identification
Aldolase 1, A isoform 8.40 40 471 P05064 7
Procollagen lysine, 2-oxoglutarate 5-dioxygenase 3 5.81 85 389 Q9R0E1 4
Vinculin 5.88 117 1160 Q64727 16
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more than 50% of the mice died because of lung metastases. Inter-
estingly, among the mice alive on day 19, the anti-GRP78 levels were
usually in the low percentile range (Figure 3C ).
Effect of Radiotherapy and Chemotherapy on GRP78
Auto-Ab Titer
To study the effect of treatments on the expression of GRP78 auto-
Abs, we chose radiotherapy and chemotherapy regimens. Accordingly,
tumor-bearingmice were exposed to 16-Gy radiation, 100-mg/kg cyclo-
phosphamide administered intraperitoneally (bolus, two injections at
5-day interval), or low-dose cyclophosphamide in the drinking water
(so-calledmetronomic chemotherapy). Radiotherapy and bolus cyclophos-
phamide are known to exert profound antitumor effects, as confirmed
in Figure 4,A andC , respectively.Metronomic cyclophosphamide ther-
apy is a therapeutic scheme proposed to have a better benefit/toxicity
balance than the conventional maximal tolerated dose regimen [15].
In this study, we observed an initial response of the tumor to metro-
nomic cyclophosphamide but a loss of efficacy on the longer term (Fig-
ure 4E ). ELISA revealed that radiotherapy led to an increase in
circulating anti-GRP78, peaking at five-fold the level observed 5 days
before the radiation exposure (Figure 4B). Of note, local irradiation of
control animals (ie, without tumor) failed to lead to any changes in anti-
GRP78 concentrations (not shown). Chemotherapy gave rise to an
opposite pattern, with a significant reduction of anti-GRP78 auto-Ab
concentration (Figure 4, D and F ). Note the continuous decrease in
anti-GRP78 auto-Ab with metronomic chemotherapy despite the lesser
inhibitory effect of this drug regimen on tumor growth (Figure 4F ).
Immune Response Toward the Different Treatments
To understand the reasons of the decrease in anti-GRP78 auto-Ab
after chemotherapy, we evaluated whether the systemic cytotoxic effects
of cyclophosphamide could influence the humoral response by anti-
body-producing lymphocytes. We therefore used flow cytometry to
evaluate potential changes in the extent of B cells in treated versus un-
treated tumor-bearing mice (Figure 5A). We observed that, whereas
radiotherapy did not alter the amounts of B-220–positive B cells, cy-
clophosphamide administration led to a 20% to 50% reduction in B
cells (Figure 5B). The reduction in B-cell numbers after chemotherapy
did correlate with a reduction in the extent of circulating IgG as de-
termined by immunoprecipitation from cyclophosphamide-exposed
mouse sera (Figure 5C). Because radiotherapy led to a similar reduc-
tion in circulating IgG despite a maintained amount of B cells, we fur-
ther examined whether antibodies could be trapped into the irradiated
tumor. Figure 5D shows that the overall detection of IgG from tumor
sections was indeed significantly increased in response to radiotherapy
(vs untreated tumors, n = 5). Immunohistochemical analysis of the
same tumor sections further revealed that GRP78 expression was also
dramatically increased in irradiated tumors (Figure 5D).
Discussion
The major findings of this study are that (i) increase in circulating
anti-GRP78 auto-Ab is associated with the detection of primary tu-
mor and metastases at earlier times than with palpation and micro-
scopic analysis of the invaded tissues, respectively; (ii) chemotherapy
and radiotherapy have opposite effects on the extent of circulating
anti-GRP78 auto-Ab, prompting caution in interpreting changes in
auto-Ab titers in response to anticancer treatments; and (iii) Cy-dyes
multiplex analysis may optimize the SERPA workflow.
An increasing number of studies report the identification of auto-
Ab in cancer patients as potential new biomarkers for cancer de-
tection and prognosis [1–14]. Although several good candidates are
making their route toward validation in larger studies, a variable pro-
portion of patients with a given cancer type are usually positive for
the considered auto-Ab. Most of these studies aiming to identify auto-
Ab as new cancer biomarkers are carried out by comparing the sera
of cancer patients with the sera of healthy volunteers or patients with
cancer-predisposing diseases (eg, polyps, cirrhosis, viral infection). The
status of patients at the time of the serum collection is therefore vari-
able, and the influence of treatments (targeting cancer or precancerous
lesions) is rarely integrated in the interpretation of the results. Another
related issue is the potential and reliability of auto-Ab–based markers
to follow the response to treatments. From a theoretical point of view,
Figure 2. Validation of GRP78 as a tumor autoantigen. (A) Immunoblot analysis with commercial anti-GRP78 of the putative GRP78 spot
from LLc tumor extracts separated on two-dimensional membranes. (B) Representative Western blot analysis of the expression of
GRP78 in host tissue and tumors (n = 4); simultaneous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) immunoblot analysis
was used as a control. (C) Representative GRP78 immunostaining on host tissue (top) and tumor (bottom) sections; immunostaining
experiments were repeated several times with similar results.
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Figure 3. Changes in the titer of anti-GRP78 auto-Ab as a marker of primary tumor growth and metastases. (A) GRP78-specific ELISA
was performed from sera collected through retro-orbital bleeding of mice before (day 0) and after (days 3, 7, 10, 14, and 17) tumor cell
injection. Results are presented as scatter plots; *P < .05, **P < .01. (B) Tumor diameters as measured with a caliper. (C) GRP78-
specific ELISA was performed at the indicated time after primary tumor removal to activate lung metastases. Results are presented
as scatter plots; *P < .05. (D) Number of lung metastases identified by histologic analysis of lungs collected from tumor-bearing mice
at the indicated time before and after surgery. Note that on day 19 in panels C and D, only data arising from surviving animals are
presented. (E) Representative CD31 immunostaining of tumor sections on days 7 and 14. Histogram represents the distribution
of CD31-positive vascular structures according the indicated sizes. (F) Representative laser Doppler imaging (LDI) pictures from LLc
tumor-bearing mice on days 7 and 14 after injection of tumor cells. The average perfusions of the tumor-bearing leg (white circle)
and of the control leg (arrowhead) can be evaluated on the basis of the colored histogram pixels.
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eradication of a tumor should lead to a decrease in TAAs and thus in
the corresponding circulating auto-Ab.
Here, we used a mouse tumor model to work with a more con-
densed process of tumor growth and consecutive metastatic spreading
than what is observed in the course of the disease in humans. Such an
animal model also allows to reduce the interindividual variability
observed with patients. A multiplex analysis was further applied to
optimize the detection of auto-Ab, through the coregistration of
the Cy5 staining of tumor cell proteins separated on two-dimensional
gels and the Cy2-channel detection of the ECL-driven chemilumi-
nescence from the peroxidase-conjugated secondary antibody. This
multiplex strategy, which advantageously replaced the conventional
approach matching the immunoblot with Coomassie blue– or silver-
stained gels, led us to identify a rather limited number of spots. From
the short list of proteins selectively recognized by the sera of tumor-
bearing mice, we have selected GRP78 (ie, the highest immune signal
after serum immunoblot analysis) to address the issues of changes in
auto-Ab titer with metastatic spreading and treatments.
GRP78, a member of the heat shock protein 70 family, plays key
roles in the ER stress response [17]. In tumor cells, ER stress is a
common phenomenon observed in response to nutrient deprivation,
acidosis, or hypoxia [18]. In these hostile conditions, GRP78 facili-
tates proper protein folding and targets misfolded protein for protea-
some degradation [18,19]. Shedding of GRP78 protein was reported
to sign the presence of cancer [18] and a recent study identified crit-
ical roles of GRP78 in tumor cell survival and angiogenesis [19].
Figure 4. Differential influence of radiotherapy and chemotherapy on GRP78 auto-Abs titer. Changes in tumor growth and seric GRP78
auto-Ab signal (detected by ELISA) observed after radiotherapy, or cyclophosphamide under bolus (100 mg/kg intraperitoneally) or
metronomic (through the drinking water) administrations. Panels A, C, and E show the effects of either treatment on tumor growth;
**P < .01 versus day 10. Bar graphs represent the effects of either treatment on GRP78 auto-Ab signal from tumor-bearing (B, D, and F).
*P < .05, **P < .01 versus day 9 (before treatment administration).
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Interestingly, anti-GRP78 auto-Abs were recently identified as bio-
markers of the clinical progression of prostate [20,21] and ovarian
cancers [22]. In these human studies, serum reactivity against
GRP78 correlated positively with natural cancer progression, allowing
to discriminate between organ-confined, locally advanced, and meta-
static prostate cancers [20] and between early stages and stages III/IV
of ovarian cancer [21]. The choice of anti-GRP78 as a generic auto-Ab
detected in our mouse tumor model is therefore supported by clinical
data validating this marker of cancer progression. In our study, the
immunogenicity of GRP78 is likely to find its origin in the overexpres-
sion and the mislocalization of GRP78 at the plasma membrane of
tumor cells (Figure 2). Importantly, we showed that anti-GRP78
auto-Ab was detected in the serum of mice well before the detection
of the tumor by palpation or caliper measurements (Figure 3, A and B).
Taking advantage of the induction of dormant lung metastases
after the removal of the primary tumor [16], we showed that an in-
crease in anti-GRP78 auto-Ab concentrations was detectable at a time
when microscopic evaluation of the lungs failed to identify metastases
(Figure 3, C and D). These results give credential to the use of anti-
GRP78 antibody as early biomarkers of both primary tumor emer-
gence and activation of dormant metastases after surgery. We found,
however, that the titer of circulating anti-GRP78 auto-Ab did not in-
crease linearly with the tumor burden (Figure 3, A and B). In par-
ticular, the onset of a functional vascularization in the tumor (Figure 3,
E and F ) was associated with an acute increase in auto-Ab detection
(see day 10 in Figure 3A).
The data establishing GRP78 as a key immunogenic protein in
our tumor model led us to evaluate whether anti-GRP78 auto-Ab
could also be exploited as a marker of the response to radiotherapy
and chemotherapy. Although we used a 16-Gy irradiation and bolus
cyclophosphamide that inhibited tumor growth to the same extent
(Figure 4, A and C ), we found that chemotherapy administration
was associated with a reduction in the serum titer of anti-GRP78
antibodies, whereas radiotherapy increased it (Figure 4, B and D).
Figure 5. Humoral immune responses of tumor-bearing mice to radiotherapy or chemotherapy. B-cell number determination from the
blood of control or treated tumor-bearing mice (see Figure 4 legend for treatment details): representative flow cytometry analyses of
B220-expressing blood cells (A) and quantification (B) are presented; *P < .05, **P < .01 (n = 3). (C) Changes in the total amounts of
circulating IgG were also determined after immunoprecipitation from the blood of tumor-bearing mice; *P < .05 (n = 3). (D) Represen-
tative pictures of immunohistochemical analyses of tumor sections documenting the trapping of IgG (left) or the extent of GRP78 protein
expression (right) in nonirradiated (top) or irradiated (bottom) tumors. These experiments were repeated on five different tumors per
condition with similar results; staining and optic conditions were strictly identical between untreated and irradiated tumors.
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We found that the decrease in anti-GRP78 auto-Ab (and circulat-
ing Ig in general) after cyclophosphamide administration could be
related to the observed net reduction in lymphocytes, in particular
the antibody-producing B-cell population (Figure 5, A and B). More-
over, the metronomic scheme of cyclophosphamide administration
used in this study, although less efficient in inhibiting tumor growth,
did not spare the anti-GRP78 titer, which also decreased with time
(Figure 4F ). Altogether, these observations stress that myelotoxic
treatments, as observed with most chemotherapeutic strategies [23–
25], could be misguiding by inadequately linking reductions in tumor
biomarker concentrations and in tumor mass.
In contrast, as anticipated, local irradiation of the tumor did
not influence the number of B cells in treated animals. The observed
radiation-driven increase in anti-GRP78 auto-Ab may instead be
related to an overall increased stress response favoring the expression
of functional GRP78 (as shown in Figure 5D); additional mech-
anisms could involve radiation-triggered degradation of GRP78 pro-
tein, thereby increasing the pool of peptides presented by the MHC
class I pathway. The observed local increase in IgG abundance in the
tumor (Figure 5D) and the overall decrease in circulating IgG after
radiation (Figure 5C ) support this hypothesis of an overall stimulated
immune response. Also, the response was tumor-selective because we
did not observe any increase in anti-GRP78 auto-Ab by irradiating
the host tissue (in non–tumor-bearing mice; not shown). Together
with the observation that, in response to radiotherapy, the circulating
anti-GRP78 auto-Ab titer increased despite the overall decrease in
circulating antibodies (Figures 4B and 5C ), our data confirm that
GRP78 is one of the key protein against which an immune response
is mounted in tumors.
In conclusion, we identified the anti-GRP78 auto-Ab as an early
seric marker of tumor and metastatic progression and showed how its
titer may be differently influenced by radiotherapy and chemotherapy.
Although not excluding the use of auto-Ab as markers of response to
conventional anticancer treatments, this study with an archetypical
auto-Ab emphasizes the need to integrate factors such as B cells’ de-
pletion or promotion of the antigen-presenting process to interpret the
data. Our study therefore brings new insights in the process of identi-
fying new biomarkers from the serological proteome by (i) drawing the
attention to the therapeutic status of cancer patients recruited in stud-
ies aiming to identify new auto-Abs as cancer biomarkers and (ii) re-
porting the integration of CyDyes multiplex technology as a way to
improve SERPA-based detection of tumor auto-Abs.
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Materials and Methods
MALDI identification. Peptides digest were desalted on C18
Geloader pipette Tips (Proxeon Biosystems, Odense, Denmark) and
directly eluted on the target with a mix (1:1 vol./vol.) of α-cyano-4-
hydroxyciannamic acid (in 7:3 vol./vol. acetonitrile/5% formic acid)
and 2,5-dihydroxybenzoic acid (in 7:3 vol./vol. acetonitrile/0.1% tri-
fluoracetic acid). Peptide mass fingerprints were obtained using a
MALDI-MX mass spectrometer (Walters). ProteinLynx Global Server
2.2.5 (Waters) was used as a peak list–generating software. Two external
calibrations were used: lock mass with ADH digest and lock mass with
1618.84 Da. The trypsin autodigestion peak at 2211.1046 Da was
used for the internal calibration. In-house Mascot 2.2 server was used
as database search engine; PMF search was performed onMus musculus
subset of the National Center for Biotechnology Information non-
redundant database (NCBInr; 138,000 entries in 2008 sequences). Pa-
rameters for peptide matching were a peptide tolerance of 100 ppm,
a maximum of one missed cleavage, carbamidomethylation was allowed
as a fixed modification, and oxidation of methionine was allowed as
a variable modification. For all protein identifications, a minimal indi-
vidual score of 64 (identity score) and expect value less than 1 were used
for the identification criteria.
QTOF identification. Peptides were analyzed by using a nanoflow
liquid chromatography coupled to tandem mass spectrometry with
electrospray ionization. (Waters) instrument on a CapLC Q-TOF2
mass spectrometer (Waters). The digests were separated by reverse-
phase liquid chromatography using a 75-μm × 150-mm reverse-phase
NanoEase column (Waters) in a CapLC (Waters) liquid chromatog-
raphy system. Mobile phase A was 95% of 0.1% formic acid in water
and 5% acetonitrile. Mobile phase B was 0.1% formic acid in aceto-
nitrile. The digest (1 μl) was injected, and the organic content of the
mobile phase was increased linearly from 5% to 40% B in 40 min-
utes and from 40% to 100% B in 5 minutes. The column effluent
was connected to a PicoTip emitter (New Objective, Woburn, MA) in-
side the Q-TOF source. Peptides were analyzed in data-dependent
acquisition mode on a Q-TOF2 (Waters) instrument. In a survey scan,
MS spectra were acquired for 1 second in the m/z range between 450
and 1500. For MS/MS raw data, peak lists were created using Distiller
(Matrix Sciences), and in-house Mascot 2.2 (Matrix Sciences) server
was used as database search engine. Enzyme specificity was set to tryp-
sin, and the maximum number of missed cleavages per peptide was set
at 1. Carbamidomethylation was allowed as a fixed modification, and
oxidation of methionine was allowed as a variable modification. Mass
tolerance for the monoisotopic precursor peptide window and MS/MS
tolerance window were set to ±0.3 Da. We also specified ESI-Q-TOF
as an instrument. The peak lists were searched against theMus musculus
subset of the National Center for Biotechnology Information non-
redundant (NCBInr) database (138,000 entries in 2008). Control
searches of all the files against the whole NCBInr database (5,454,477
entries in 2008) were used to confirm the identification. For all protein
identifications in MS/MS, a minimal individual peptide score of 36
(if less than this score, no identity or homology was found for the ana-
lyzed peptides) and expect value less than 1were used for the initial iden-
tification criteria. Moreover, the correlation between theoretical pI and
molecular mass of the protein with the position of the corresponding
spot in the two-dimensional gel was also taken into account.
Results
We identified 40 serum-labeled spots on the two-dimensional
blots. The proteins of interest were excised from preparative gels
and digested with trypsin, and the peptide mixtures were analyzed
by MS. This led to the identification of 24 different proteins with
satisfying scores (see criteria; Table W1), among which 12 were rec-
ognized by pooled sera of tumor-bearing mice. The extensive data
sets corresponding to the identification of the tumor serum–positive
antigens are provided in Table W2.
Figure W1. Schematic overview of the multiplex-based detection
of auto-Ab. Cy5-labeling of tumor extracts is coregistered with en-
hanced chemiluminescence (ECL)–based detection of the peroxidase-
conjugated secondary antibody using the Cy2 channel detection.
Figure W2. Representative anti-GRP78 ELISA calibration. The 96-well plates coated with 5 μg/ml recombinant GRP78 protein (Stressgen)
were used. Specific hybridization using serial dilutions of GRP78 antibody (BD Pharmingen) was measured with a peroxidase-conjugated
antimouse IgG antibody (dilution, 1:10,000) and addition of 3,3′,5,5′-tetramethylbenzidine (Calbiochem). Plates were read at 450 nm in a
VictorX4 microplate reader.
Table W1. List of Identified Tumor Proteins Detected by Two-dimensional Immunoblot Analysis with the Sera of Control and/or Tumor-Bearing Mice.
Proteins Recognized by Control Mouse Serum Proteins Recognized by Tumor-Bearing Mouse Serum
Inner membrane protein mitochondrial, isoform CRA_a and b + +
Villin 2 + +
Glucose-regulated protein GRP78 +
Sorting-nexin 9 +
Heat shock protein 1 + +
Heterogeneous nuclear ribonucleoprotein L +
Heterogeneous nuclear ribonucleoprotein K +
Lamin A/C +
Septin 11 +
Vimentin + +
Lap 3 + +
Similar to actin +
Pyrophosphatase +
Lectin, galactose binding, soluble 3 + +
Alanyl-tRNA synthetase +
Ubiquitin specific protease 5 (isopeptidase T) +
Aldolase 1, A isoform +
gamma-Actin +
Annexin A11 +
Heat shock protein HSP 90-beta Hsp 84 +
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 + +
Protein 40 kDa + +
Gelsolin-like capping protein +
Vinculin +
Table W2. List of Tumor Antigens and Related Digested Peptides Identified on the Basis of Their Mass Fingerprint.
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